CYT — Cyteir Therapeutics Balance Sheet
0.000.00%
Last trade - 00:00- $111.95m
- -$17.29m
- 44
- 35
- 77
- 51
Annual balance sheet for Cyteir Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
|---|---|---|---|---|
| Period Length: | — | — | — | — |
| Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K |
| Standards: | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final |
| Cash and Equivalents | ||||
| Cash and Short Term Investments | 29 | 10.9 | 190 | 147 |
| Net Total Receivables | 0.164 | 0.063 | 0.038 | — |
| Prepaid Expenses | ||||
| Total Current Assets | 30.4 | 12.1 | 193 | 149 |
| Gross Property, Plant And Equipment | ||||
| Accumulated Depreciation | ||||
| Net Property, Plant And Equipment | 0.788 | 1.29 | 2.06 | 3.77 |
| Other Long Term Assets | ||||
| Total Assets | 31.4 | 13.7 | 195 | 153 |
| Accounts Payable | ||||
| Accrued Expenses | ||||
| Notes Payable / Short Term Debt | ||||
| Total Current Liabilities | 1.97 | 3.14 | 7.51 | 5.32 |
| Total Long Term Debt | ||||
| Total Debt | ||||
| Total Other Liabilities | ||||
| Total Liabilities | 2.29 | 4.36 | 8.1 | 6.95 |
| Redeemable Preferred Stock | ||||
| Common Stock | ||||
| Additional Paid In Capital | ||||
| Retained Earnings (Accumulated Deficit) | ||||
| Total Equity | 29.1 | 9.38 | 187 | 146 |
| Total Liabilities & Shareholders' Equity | 31.4 | 13.7 | 195 | 153 |
| Total Common Shares Outstanding |